You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Nexstim: More sales with licenses
Nexstim is a technologically advanced niche player in large markets supported by megatrends. Nexstim is still in an early stage of commercialization and seeking sustainable positive earnings. The valuation of the share relies heavily on future expectations of system sales growth, licensing income recognition and expansion of the new clinic network model. We find the valuation reasonable but it does not provide investors sufficient expected return relative to the risks at the current level. Analyst Antti Siltanen comments on Nexstim as an investment.
Extensive report on Nexstim: https://www.inderes.fi/en/system/files/company-reports/nexstim_extensive_report_2023.pdf
More about Nexstim as an investment: https://www.inderes.se/companies/Nexstim
Content:
00:00 Introduction
00:15 Nexstim as a company
02:25 Business model
04:50 Market and competition
07:07 Value drivers and risk factors
09:17 Strategy
10:00 Financial position
11:11 Estimates and valuation